

1. Sales January to March 2003 and 2004

	2003	2004	% change	
	CHF m	CHF m	In CHF	In local currencies
January - March				
Pharmaceuticals	4,888	5,646	16	17
Roche Prescription	3,053	3,546	16	16
Genentech Prescription	777	923	19	29
Chugai Prescription	656	748	14	12
Prescription	4,486	5,217	16	18
OTC	402	429	7	5
Diagnostics	1,725	1,908	11	10
Continuing Businesses	6,613	7,554	14	15
Vitamins and Fine Chemicals ¹	743	-	-100	-100
Roche Group	7,356	7,554	3	3

¹ consolidated until 30 September 2003

2. Quarterly local sales growth by Division in 2003 and 2004

	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003
Pharmaceuticals	25	28	20	17
Roche Prescription	9	13	24	16
Genentech Prescription	24	22	21	29
Chugai Prescription	242	274	13	12
Prescription	25	28	21	18
OTC	23	28	6	5
Diagnostics	7	7	12	10
Continuing Businesses	20	22	18	15
Vitamins and Fine Chemicals ¹	-4	-7	-100	-100
Roche Group	17	19	6	3

¹ consolidated until 30 September 2003

3. Core Division's quarterly sales in 2003 and 2004

CHF millions	Q1 2003	Q2 2003	Q3 2003	Q4 2003	Q1 2004
Pharmaceuticals	4,888	5,237	5,373	6,053	5,646
Roche Prescription	3,053	3,210	3,321	3,659	3,546
Genentech Prescription	777	814	875	916	923
Chugai Prescription	656	755	731	1,014	748
Prescription	4,486	4,779	4,927	5,589	5,217
OTC	402	458	446	464	429
Diagnostics	1,725	1,820	1,837	2,027	1,908
Continuing Businesses	6,613	7,057	7,210	8,080	7,554

4. Top 20 prescription medicines sales¹ and local growth² in the first quarter of 2004:
US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	782	33%	484	21%	39	177%	259	56%
Neo Recormon/Epogin	489	5%	-	-	171	7%	318	4%
Pegasys/Copegus	391	236%	191	194%	8	-	192	281%
Cellcept	369	23%	176	18%	5	34%	188	29%
Rocephin	369	4%	219	13%	11	3%	139	-8%
Herceptin	328	27%	136	16%	22	28%	170	39%
Xenical	146	1%	27	-14%	-	-	119	6%
Roaccutan/Accutane	116	-33%	53	-46%	-	-	63	-13%
Xeloda	115	-11%	36	-49%	4	-	75	34%
Nutropin/Protropin	109	11%	106	11%	-	-	3	-7%
Kytril	109	28%	46	43%	26	4%	37	31%
Tamiflu	108	-1%	-8	-	87	6%	29	191%
Dilatrend	104	14%	-	-	-	-	104	14%
Cymevene/Valcyte	86	38%	51	41%	-	-	35	32%
Pulmozyme	84	15%	48	16%	-	-	36	13%
Neutrogen	76	6%	-	-	76	6%	-	-
Activase/TNKase	63	-1%	56	-4%	-	-	7	39%
Madopar	61	6%	-	-	4	4%	57	6%
Inhibace/Inhibace +	57	13%	-	-	3	10%	54	13%
Lexotan	52	-1%	-	-	4	30%	48	-2%
Fuzeon	31	-	20	-	-	-	11	-

¹ Roche Rx, Genentech Rx and Chugai Rx combined

² versus 2003

5. Top 20 prescription medicines quarterly local sales growth¹ in 2003 and 2004

	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003
MabThera/Rituxan	37%	32%	30%	33%
NeoRecormon/Epogin	139%	124%	7%	5%
Pegasys/Copegus	1450%	1260%	610%	236%
Cellcept	17%	26%	20%	23%
Rocephin	-4%	2%	22%	4%
Herceptin	32%	26%	19%	27%
Xenical	-11%	-11%	-11%	1%
Roaccutan/Accutane	-49%	-40%	-25%	-33%
Xeloda	50%	10%	3%	-11%
Nutropin/Protropin	8%	4%	9%	11%
Kytril	16%	11%	3%	28%
Tamiflu	-	-	207%	-1%
Dilatrend	22%	18%	17%	14%
Cymevene/Valcyte	1%	37%	5%	38%
Pulmozyme	15%	6%	26%	15%
Neutrogin	-	-	-6%	6%
Activase/TNKase	10%	2%	-15%	-1%
Madopar	1%	6%	4%	6%
Inhibace/Inhibace +	-13%	3%	-4%	13%
Lexotan	-11%	-3%	-11%	-1%

¹ Roche Rx, Genentech Rx and Chugai Rx combined

6. Prescription medicines quarterly local sales growth¹ US in 2003 and 2004

	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003
MabThera/Rituxan	33%	30%	22%	21%
NeoRecormon/Epogin	-	-	-	-
Pegasys/Copegus	-	-	1489%	194%
Cellcept	5%	25%	21%	18%
Rocephin	4%	9%	50%	13%
Herceptin	20%	20%	11%	16%
Xenical	-1%	-24%	-13%	-14%
Roaccutan/Accutane	-59%	-52%	-36%	-46%
Xeloda	57%	-15%	-31%	-49%
Nutropin/Protropin	8%	4%	9%	11%
Kytril	23%	12%	-3%	43%
Tamiflu	-	-	355%	-
Dilatrend	-	-	-	-
Cymevene/Valcyte	-1%	57%	-5%	41%
Pulmozyme	13%	3%	36%	16%
Neutrogen	-	-	-	-
Activase/TNKase	8%	3%	-7%	-4%
Madopar	-	-	-	-
Inhibace/Inhibace +	-	-	-	-
Lexotan	-	-	-	-

¹ Roche Rx and Genentech Rx combined

7. Prescription medicines quarterly local sales growth Japan¹ in 2003 and 2004

	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003
MabThera/Rituxan	24%	39%	153%	177%
NeoRecormon/Epogin	-	-	2%	7%
Pegasys/Copegus	-	-	-	-
Cellcept	19%	22%	20%	34%
Rocephin	25%	6%	22%	3%
Herceptin	58%	40%	16%	28%
Xenical	-	-	-	-
Roaccutan/Accutane	-	-	-	-
Xeloda	-	-	-	-
Nutropin/Protropin	-	-	-	-
Kytril	13%	9%	8%	4%
Tamiflu	139%	-	117%	6%
Dilatrend	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Pulmozyme	-	-	-	-
Neutrogin	-	-	-6%	6%
Activase/TNKase	-	-	-	-
Madopar	-1%	-2%	3%	4%
Inhibace/Inhibace +	-5%	-63%	-28%	10%
Lexotan	19%	-16%	-5%	30%

¹ Chugai Rx

8. Prescription medicines quarterly local sales growth Europe/Rest of World¹ in 2003 and 2004

	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002	Q4 2003 vs. Q4 2002	Q1 2004 vs. Q1 2003
MabThera/Rituxan	53%	38%	42%	56%
NeoRecormon/Epogin	37%	33%	14%	4%
Pegasys/Copegus	442%	351%	290%	281%
Cellcept	33%	29%	21%	29%
Rocephin	-17%	-7%	-9%	-8%
Herceptin	43%	31%	31%	39%
Xenical	-15%	-7%	-11%	6%
Roaccutan/Accutane	-31%	-13%	-12%	-13%
Xeloda	38%	35%	27%	34%
Nutropin/Protropin	12%	5%	-4%	-7%
Kytril	8%	12%	8%	31%
Tamiflu	-	-	154%	191%
Dilatrend	22%	18%	17%	14%
Cymevene/Valcyte	1%	9%	12%	32%
Pulmozyme	19%	12%	10%	13%
Neutrogen	-	-	-	-
Activase/TNKase	30%	1%	-49%	39%
Madopar	2%	6%	3%	6%
Inhibace/Inhibace +	-13%	11%	-1%	13%
Lexotan	-12%	-3%	-12%	-2%

¹ Roche Rx